R&D Q2 clinical trials round-up: April to June 2025 The second quarter of 2025 has seen a surge of clinical trial activity across the pharmaceutical and biotech landscape.
News AZ grabs FDA nod for Ultomiris in rare kidney disease IgAN AstraZeneca has staked a claim to the increasingly crowded IgAN market with an accelerated approval from the FDA for Ultomiris, its fifth indication.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
